教授，主任医师，博士生导师，中央保健会诊专家

北京大学第一医院感染疾病科主任，兼任肝病中心主任

中华医学会感染病学分会主任委员

中国医院协会抗菌药物合理应用工作委员会主任委员

中国医师协会感染病医师分会副会长

中华医学会全科医师教育学院副院长

国家免疫规划专家咨询委员会委员

国家卫健委传染病标准委员会委员

国家卫健委新冠病毒肺炎医疗救治专家组成员

国家卫健委新冠病毒肺炎恢复期血浆治疗专家组成员

境外抗疫医疗专家组国家顾问团成员

国务院应对新冠病毒肺炎联防联控机制科研攻关专家组成员

科技部新冠肺炎国际合作专家组成员

美国《临床感染病》杂志编委，《中华传染病杂志》和《中华临床感染病杂志》副总编辑， 《临床肝胆病学》共同主编等。

Gui-Qiang Wang, MD

Professor, Chief physician

Chairman, Department of infectious diseases,

Director, Center for liver disease, Peking University first hospital;

President, Society of Infectious Diseases, Chinese Medical Association;

Chairman, Antimicrobial Stewardship Working Committee, Chinese hospital association;

Vice President, Infectious Disease Physicians Branch, Chinese Medical Doctor Association;

Vice President, General Practitioner Education College, Chinese Medical Association;

Member, National Immunization Program Expert Advisory Committee;

Member, National Health Commission Infectious Diseases Standards Committee;

Member, National Health Commission COVID-19 Medical Treatment Expert Group;

Member, National Health Commission COVID-19 Convalescent Plasma Therapy Expert Group;

Member, National Advisory Board of Overseas Anti-epidemic Medical Expert Group;

Member, The State Council Expert Group on Joint prevention and control mechanism of COVID-19;

Member, COVID-19 International Cooperation Expert Group, Ministry of Science and Technology

王贵强教授自COVID-19疫情爆发后，作为国家卫生健康委员会医疗救治专家组成员，到安徽蚌埠和阜阳等地指导重症和危重症患者救治。参加中国COVID-19诊断和治疗方案第五版、第六版和第七版的编写和更新工作;参加恢复期血浆治疗COVID-19治疗方案的编写工作。

受国家卫生健康委员会和外交部委托，向世界各国(160余国家)介绍中国诊断和治疗方案。多次参加国务院联防联控新闻发布会，介绍新冠肺炎诊疗方案更新，解答公众和媒体的提问，进行科普宣教等。

主持国家科技部应急项目“法匹拉韦联合托珠单抗治疗新冠肺炎的多中心临床研究”，主持“COVID-19恢复期患者核酸”复阳“发生机制、转归及治疗干预的研究”等。

Since the outbreak of COVID 19, professor wang guiqiang, as a member of the medical treatment expert group of the national health commission, has guided clinical diagnosis and treatment, and participated in the compilation and update of the fifth, sixth and seventh version of the Chinese COVID 19 diagnosis and treatment protocol. Participated in the preparation of the convalescent plasma therapy protocol for COVID-19;

On behalf of the National Health Commission, he introduced China's diagnosis and treatment protocol to more than 160 countries in the world. On behalf of the National Health Commission, he participated in the press conferences of the state council on joint prevention and control for many times, presented the Protocol, answered questions from the public and the media, and explained COVID-19 prevention and control knowledge to the public.

Leading the emergency project of the ministry of science and technology "Favipiravir Combined Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study", and leading “The study on the mechanism, outcome and therapeutic intervention of COVID -19 convalescent patients that the nucleic acid reversion".